Immunotherapy or Antiangiogenic Therapy Plus Chemotherapy As First‐line Treatment of Patients with PD‐L1(‐) Advanced Non‐squamous Non‐small Cell Lung Cancer in a Chinese Cohort

Ruolan Xia,Yanying Li,Ling Yang,Meijuan Huang
DOI: https://doi.org/10.1002/cam4.6101
IF: 4.711
2023-01-01
Cancer Medicine
Abstract:Purpose: For patients with advanced nonsquamous non-small cell lung cancer (NSCLC), immunotherapy or antiangiogenic therapy combined with pemetrexed and cisplatin/carboplatin have both shown significant efficacy at programmed cell death ligand 1 (PD-L1) levels of <1%. Our study aimed to compare two first-line regimens for patients with advanced nonsquamous NSCLC who were negative for PD-L1. Methods: A retrospective cohort study was conducted comparing the outcomes of patients with advanced PD-L1(--) nonsquamous NSCLC who were treated with antiangiogenic therapy plus chemotherapy (A Group) to those who were treated with anti-PD-L1 monoclonal antibodies plus chemotherapy (mAbs) (B Group). Both regimens were evaluated for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and side effects. Results: 114 patients were enrolled in the study, 82 in Group A and 32 in Group B. Those in Group A had a longer median PFS (9.8 vs. 6.7 months, p = 0.025). The OS was also achieved (p = 0.058). No statistically significant difference was seen in ORR (52.4% vs. 50.0%, p = 0.815) or DCR (93.9% vs. 87.5%, p = 0.225) between the two groups. Patients in the A group who did not smoke and did not have specific metastases could benefit from survival. Adverse events (AEs) in both groups were tolerated. Conclusion: Bevacizumab plus chemotherapy outperformed immunotherapy plus chemotherapy in terms of PFS.
What problem does this paper attempt to address?